

# Causes of Effects and Effects of Causes

Judea Pearl  
University of California, Los Angeles  
Computer Science Department  
Los Angeles, CA, 90095-1596, USA  
judea@cs.ucla.edu

June 20, 2014

## Abstract

## 1 Introduction

I am grateful to the editors for inviting me to comment on the paper by Dawid, Fienberg, and Faigman (2013) (henceforth DFF), in which they justifiably emphasize the fundamental distinction between “Effect of Causes” (EoC) and “Causes of Effect” (CoE).

My aim in this comment is to share with readers a progress report on what has been accomplished on the question of “causes of effects,” CoE, how far we have come in using population data to decide individual cases, and how well we can answer questions that law makers ask about individual’s guilt or innocence. I hope this account convinces readers that the analysis of “causes of effects,” CoE, has not lagged behind that of EoC. Both modes of reasoning enjoy a solid mathematical basis, endowed with powerful tools of analysis, and researchers on both fronts now possess solid understanding of applications, identification conditions, and estimation techniques.

## 2 The Logic of Counterfactuals

A good place to start is the mathematization of counterfactuals, a development that is responsible, at least partially, for legitimizing counterfactuals in

scientific discourse,<sup>1</sup> and which has reduced the quest for “causes of effects” to an exercise in logic.

At the center of this logic lies a model,  $M$ , consisting of a set of equations similar to those used by physicists, geneticists (Wright, 1921) economists (Haavelmo, 1943) and social scientists (Duncan, 1975) to articulate scientific knowledge in their respective domains.  $M$  consists of two sets of variables,  $U$  and  $V$ , and a set  $F$  of equations that determine how values are assigned to each variable  $V_i \in V$ . Thus for example, the equation

$$v_i = f_i(v, u)$$

describes a physical process by which Nature *examines* the current values,  $v$  and  $u$ , of all variables in  $V$  and  $U$  and, accordingly, *assigns* variable  $V_i$  the value  $v_i = f_i(v, u)$ . The variables in  $U$  are considered “exogenous,” namely, background conditions for which no explanatory mechanism is encoded in model  $M$ . Every instantiation  $U = u$  of the exogenous variables corresponds to defining a “unit,” or a “situation” in the model, and uniquely determines the values of all variables in  $V$ . Therefore, if we assign a probability  $P(u)$  to  $U$ , it defines a probability function  $P(v)$  on  $V$ . The probabilities on  $U$  and  $V$  can best be interpreted as the proportion of the population with a particular combination of values on  $U$  and/or  $V$ .

The basic counterfactual entity in structural models is the sentence: “ $Y$  would be  $y$  had  $X$  been  $x$  in situation  $U = u$ ,” denoted  $Y_x(u) = y$ , where  $Y$  and  $X$  are any variables in  $V$ . The key to interpreting counterfactuals is to treat the subjunctive phrase “had  $X$  been  $x$ ” as an instruction to make a minimal modification in the current model, so as to ensure the antecedent condition  $X = x$ . Such a minimal modification amounts to replacing the equation for  $X$  by a constant  $x$ , which may be thought of as an external action  $do(X = x)$ , not necessarily by a human experimenter, that imposes the condition  $X = x$ . This replacement permits the constant  $x$  to differ from the actual value of  $X$  (namely  $f_x(v, u)$ ) without rendering the system of equations inconsistent, thus allowing all variables, exogenous as well as endogenous, to serve as antecedents.

Letting  $M_x$  stand for a modified version of  $M$ , with the equation(s) of  $X$  replaced by  $X = x$ , the formal definition of the counterfactual  $Y_x(u)$  reads (Balke and Pearl, 1994a,b):

$$Y_x(u) \stackrel{\Delta}{=} Y_{M_x}(u). \tag{1}$$

In words: The counterfactual  $Y_x(u)$  in model  $M$  is defined as the solution for  $Y$  in the “surgically modified” submodel  $M_x$ . Galles and Pearl (1998) and

---

<sup>1</sup>DFP’s article makes generous use of counterfactuals, which attests to the impact of this development. For discussions concerning the place of counterfactuals in science, including their role in defining “causes of effects” see (Dawid, 2000; Pearl, 2000b).

Halpern (1998) have given a complete axiomatization of structural counterfactuals, embracing both recursive and non-recursive models. (see also Pearl, 2009, Chapter 7). They showed that the axioms governing recursive structural counterfactuals are identical to those used in the potential outcomes framework, hence the two systems are logically identical – a theorem in one is a theorem in the other. This means that relying on structural models as a basis for counterfactuals does not impose additional assumptions beyond those routinely invoked by potential outcome practitioners. Consequently, going from effects to causes does not require extra mathematical machinery beyond that used in going from causes to effects.

Since our model  $M$  consists of a set of structural equations, it is possible to calculate probabilities that might at first appear nonsensical. As noted above the probability distribution on  $U$ ,  $P(u)$ , induces a well defined probability distribution on  $V$ ,  $P(v)$ . As such, it not only defines the probability of any single counterfactual,  $Y_x = y$ , but also the joint distribution of all counterfactuals. As also noted above these probabilities refer to the proportion of individuals in the population with specific *counterfactual* values that may or may not be observed. Thus the probability of the Boolean combination, “ $Y_x = y$  AND  $Z_{x'} = z$ ” for variables  $Y$  and  $Z$  in  $V$  and two different values of  $X$ ,  $x$  and  $x'$ , is well-defined even though it is impossible for both outcomes to be simultaneously observed as  $X = x$  and  $X = x'$  cannot be concurrently true.

To answer CoE type questions, such as “if  $X$  were  $x_1$  would  $Y$  be  $y_1$  for individuals for whom in fact  $X$  is  $x_0$  and  $Y$  is  $y_0$ ” we need to compute the conditional probability  $P(Y_{x_1} = y_1 | Y = y_0, X = x_0)$ . This probability, that is the proportion of the population with this combination of counterfactual values, is well-defined once the structural equations and the distribution of exogenous variables,  $U$ , is known.

In general, the probability of the counterfactual sentence  $P(Y_x = y|e)$ , where  $e$  is any information about an individual, can be computed by the 3-step process:

**Step 1 (abduction):** Update the probability  $P(u)$  to obtain  $P(u|e)$ .

**Step 2 (action):** Replace the equations corresponding to variables in set  $X$  by the equations  $X = x$ .

**Step 3 (prediction):** Use the modified model to compute the probability of  $Y = y$ .

In temporal metaphors, Step 1 explains the past ( $U$ ) in light of the current evidence  $e$ ; Step 2 bends the course of history (minimally) to comply with the

hypothetical antecedent  $X = x$ ; finally, Step 3 predicts the future ( $Y$ ) based on our new understanding of the past and our newly established condition,  $X = x$ .

Pearl (2009, pp. 296–299; 2012) gives several examples illustrating the simplicity of this computation and how CoE-type questions can be answered when the model  $M$  is known. If  $M$  is not known, but is assumed to take a parametric form, one can use population data to estimate the parameters and, subsequently, all counterfactual queries can be answered, including those that pertain to causes of individual cases (Pearl, 2009, pp. 389–391; 2012). Thus the challenge of reasoning from group data to individual cases has been met.

When the model  $M$  is not known, we can prove that, in general, probabilities of causes are not identifiable from experimental, or observational data. However, using group data with observations about an individual, tight bounds can be derived, which can be quite informative.

We will illustrate these bounds in an example taken from judicial context similar to the one considered by DFF.

### 3 Legal Responsibility from Experimental and Nonexperimental Data

A lawsuit is filed against the manufacturer of drug  $x$ , charging that the drug is likely to have caused the death of Mr. A, who took the drug to relieve back pains. The manufacturer claims that experimental data on patients with back pains show conclusively that drug  $x$  may have only minor effect on death rates. However, the plaintiff argues that the experimental study is of little relevance to this case because it represents average effects on *all* patients in the study, not on patients like Mr. A who did not participate in the study. In particular, argues the plaintiff, Mr. A is unique in that he used the drug on his own volition, unlike subjects in the experimental study who took the drug to comply with experimental protocols. To support this argument, the plaintiff furnishes nonexperimental data on patients who, like Mr. A, chose drug  $x$  to relieve back pains, but were not part of any experiment. The court must now decide, based on both the experimental and nonexperimental studies, whether it is “more probable than not” that drug  $x$  was in fact the cause of Mr. A’s death.

This example falls under the category of “causes of effects” because it concerns situation in which we observe both the effect,  $Y = y$ , and the putative cause  $X = x$  and we are asked to assess, counterfactually, whether the former would have occurred absent the latter.

Assuming binary events, with  $X = x$  and  $Y = y$  representing treatment

and outcome, respectively, and  $X = x'$ ,  $Y = y'$  their negations, our target quantity can be formulated directly from the English sentence:

“Find the probability that if  $X$  had been  $x'$ ,  $Y$  would be  $y'$ , given that, in reality,  $X$  is  $x$  and  $Y$  is  $y$ .”

to give:

$$PN(x, y) = P(Y_{x'} = y' | X = x, Y = y) \quad (2)$$

This counterfactual quantity, which Robins and Greenland (1989) named “probability of causation” and Pearl (2000a, p. 296) named “probability of necessity” (PN), to be distinguished from two other nuances of “causation,” captures the “but for” criterion according to which judgment in favor of a plaintiff should be made if and only if it is “more probable than not” that the damage would not have occurred *but for* the defendant’s action (Robertson, 1997). In contrast, the “probability of causation” (PC\*) measure proposed by Dawid, Fienberg, and Faigman:

$$PC^* = P(Y'_x = y' | Y_x = y)$$

represents the probability that a person who took the drug under experimental conditions and died,  $Y_x = y$ , would be alive had he not been assigned the drug,  $Y_{x'} = y'$ . It thus represents the probability that the drug was the cause of death of a subject who died in the experimental setup. Very few court cases deal with deaths under experimental circumstances; most deal with deaths, damage, or injuries that took place under natural, every day conditions, for which the DFF’s measure is inapplicable.

Having written a formal expression for PN, Eq. (2), we can move on to the identification phase and ask what assumptions would permit us to identify PN from empirical studies, be they observational, experimental or a combination thereof.

This problem was analyzed in Pearl (2000a, Chapter 9) and yielded the following results:

**Theorem 1** *If  $Y$  is monotonic relative to  $X$ , i.e.,  $Y_1(u) \geq Y_0(u)$ , then PN is identifiable whenever the causal effect  $P(y|do(x))$  is identifiable and, moreover,*

$$PN = \frac{P(y) - P(y|do(x'))}{P(x, y)} \quad (3)$$

or,<sup>2</sup>

$$PN = \frac{P(y|x) - P(y|x')}{P(y|x)} + \frac{P(y|x') - P(y|do(x'))}{P(x, y)}. \quad (4)$$

---

<sup>2</sup>Equation (4) is obtained from (3) by writing  $P(y) = P(y|x)P(x) + P(y|x')(1 - P(x))$ .

The first term on the r.h.s. of (4) is the familiar excess risk ratio (ERR) that epidemiologists have been using as a surrogate for PN in court cases (Cole, 1997; Greenland, 1999; Robins and Greenland, 1989). The second term represents a *correction* needed to account for confounding bias, that is,  $P(y|do(x')) \neq P(y|x')$  or, put in words, when the proportion of population for whom  $Y = y$  when  $X$  is set to  $x'$  for everyone is not the same as the proportion of the population for whom  $Y = y$  among those observed to acquire the value  $X = x'$ .

Equation (4) thus provides a more refined measure of causation, which can be used for monotonic  $Y_x(u)$  whenever the causal effect  $P(y|do(x))$  can be estimated, from either randomized trials or graph-assisted observational studies (e.g., through the back-door criterion (Pearl, 1993) or the *do*-calculus). More significantly, it has also been shown (Tian and Pearl, 2000) that the expression in (3) provides a lower bound for PN in the general, nonmonotonic case. In particular, the tight upper and lower bounds on PN are given by:

$$\max \left\{ 0, \frac{P(y) - P(y|do(x'))}{P(x, y)} \right\} \leq PN \leq \min \left\{ 1, \frac{P(y'|do(x')) - P(x', y')}{P(x, y)} \right\} \quad (5)$$

In drug-related litigation, it is not uncommon to obtain data from both experimental and observational studies. The former is usually available at the manufacturer or the agency that approved the drug for distribution (e.g., FDA), while the latter is easy to obtain by random surveys of the population. If it is the case that the experimental and survey data have been drawn at random from the same population, then the experimental data can be used to estimate the counterfactuals of interest, e.g.,  $P(Y_x = y)$  for the observational as well as experimental sampled populations. In such cases, the standard lower bound used by epidemiologists to establish legal responsibility, the Excess Risk Ratio, can be improved substantially using the corrective term of Eq. (4). Likewise, the upper bound of Eq. (5) can be used to exonerate drug-makers from legal responsibility. Cai and Kuroki (2006) analyzed the finite-sample properties of PN. Yamamoto (2012) used instrumental variables to derive similar bounds for subpopulations permitting effect identification.

## 4 Numerical Example

To illustrate the usefulness of the bounds in Eq. (5), consider the (hypothetical) data associated with the two studies shown in Table 1. (In the analyses below, we ignore sampling variability, that is, we assume that our population is of infinite size.)

|                    | Experimental |          | Nonexperimental |      |
|--------------------|--------------|----------|-----------------|------|
|                    | $do(x)$      | $do(x')$ | $x$             | $x'$ |
| Deaths ( $y$ )     | 16           | 14       | 2               | 28   |
| Survivals ( $y'$ ) | 984          | 986      | 998             | 972  |

Table 1:

The experimental data provide the estimates

$$P(y|do(x)) = 16/1000 = 0.016, \quad (6)$$

$$P(y|do(x')) = 14/1000 = 0.014; \quad (7)$$

while the nonexperimental data provide the estimates

$$P(y) = 30/2000 = 0.015, \quad (8)$$

$$P(y, x) = 2/2000 = 0.001, \quad (9)$$

$$P(y|x) = 2/1000 = 0.002, \quad (10)$$

$$P(y|x') = 28/1000 = 0.028. \quad (11)$$

Assuming that drug  $x$  can only cause (but never prevent) death, monotonicity holds and Theorem 1 (Eq. 4) yields

$$\begin{aligned} PN &= \frac{P(y|x) - P(y|x')}{P(y|x)} + \frac{P(y|x') - P(y|do(x'))}{P(x, y)} = \\ &= \frac{0.002 - 0.028}{0.002} + \frac{0.028 - 0.014}{0.001} = -13 + 14 = 1 \end{aligned} \quad (12)$$

We see that while the observational excess risk ratio ERR is negative ( $-13$ ), giving the impression that the drug is actually preventing deaths, the bias-correction term ( $+14$ ) rectifies this impression and sets the probability of necessity (PN) to unity. Moreover, since the lower bound of Eq. (5) becomes 1, we conclude that  $PN = 1.00$  even without assuming monotonicity. Thus, the plaintiff was correct; barring sampling errors, the data provide us with 100% assurance that drug  $x$  was in fact responsible for the death of Mr. A. Note that DFF's proposal of using the experimental excess risk ratio  $1 - 1/RR$  would yield a much lower result:

$$\frac{P(y|do(x)) - P(y|do(x'))}{P(y|do(x))} = \frac{0.016 - 0.014}{0.016} = 0.125. \quad (13)$$

which does not meet the “more probable than not” requirement.<sup>3</sup>

What the experimental study does not reveal is that, given a choice, terminal patients tend to avoid drug  $x$ . That is, the 14 patients in the experimental study who did not take the drug and died anyway would have avoided the drug if they were in the nonexperimental study. In fact, as our analysis above shows, there are no terminal patients who would choose  $x$  (given the choice). If there were terminal patients that would choose  $x$ , given the choice, then by randomization some of these patients (50% in our example) would be in the control group in the experimental data. As a result, the proportion of deaths in the control group in the experimental data,  $P(y_{x'})$  would be higher than the proportion of terminal patients in the nonexperimental data,  $P(y, x')$ . However, examining the data in our hypothetical example, we observe that  $P(y_{x'}) = P(y, x') = .0014$  implying that there are no terminal patients in the nonexperimental data who choose the treatment condition. As such, any individual in the nonexperimental data who choose the treatment and died, must have died because of the treatment as they were not terminal.

The numbers in Table 1 were obviously contrived to represent an extreme case and so facilitate a qualitative explanation of the validity of (12). Nevertheless, it illustrates decisively that a combination of experimental and nonexperimental studies may unravel what experimental studies alone will not reveal and, in addition, that such combination may provide a necessary test for the adequacy of the experimental procedures. For example, if the frequencies in Table 1 were slightly different, they could easily yield a PN value greater than unity in (12), thus violating consistency,  $P(y|do(x)) \geq P(x, y)$ . Such violation must be due to incompatibility of experimental and nonexperimental groups, or an improperly conducted experiment.

This last point may warrant a word of explanation, lest the reader wonder why two data sets—taken from two separate groups under different experimental conditions—should constrain one another. The explanation is that certain quantities in the two subpopulations are expected to remain invariant to all these differences, provided that the two subpopulations were sampled randomly from the population at large. These invariant quantities are simply

---

<sup>3</sup>The difference between DFF’s  $PC^*$  and  $PN$  represents not merely an improvement of bounds but a profound conceptual difference in what the correct question is for CoE. Using DFF’s notation we have  $PC^* = Pr(R_0 = 0|R_1 = 1)$  and  $PN = Pr(R_0 = 0|A = 1, R = 1)$ .  $PC^*$  is the wrong measure to use in legal context because it does not take into account the possibility that plaintiffs who chose the treatment voluntarily are more likely to be in need of such treatment, as well as more capable of obtaining it. The same goes for personal decision making;  $PC^*$  does not take into account the fact that, if I took aspirin and my headache is gone, I am the type of person who takes aspirin when feeling headache. Formally, while  $P = 1$  and  $R = 1$  imply  $R_1 = 1$  the converse does not hold; the former is the more specific reference class.



the causal effects probabilities,  $P(y|do(x'))$  and  $P(y|do(x))$ . Although these probabilities were not measured in the observational group, they must nevertheless be the same as those measured in the experimental group (ignoring differences due to sampling variability). The invariance of these quantities implies the inequalities of (5).

The example of Table 1 shows that combining data from experimental and observational studies which, taken separately, may indicate no causal relations between  $X$  and  $Y$ , can nevertheless bring the lower bound of Eq. (5) to unity, thus implying causation *with probability approaching one*.

Such extreme results demonstrate that a counterfactual quantity PN which at first glance appears to be hypothetical, ill-defined, untestable and, hence, unworthy of scientific analysis is nevertheless definable, testable and, in certain cases, e.g., when monotonicity holds, even identifiable. Moreover, the fact that, under certain combinations of data, and making no assumptions whatsoever, an important legal claim such as “the plaintiff would be alive had he not taken the drug” can be ascertained with probability approaching one, is a remarkable tribute to formal analysis.<sup>4</sup>

## 5 How informative are the PN bounds?

To see how informative the bounds are, and how sensitive they are to variations in the experimental and observational data, consider the following example. Assume that the population of patients contains a fraction  $r$  of individuals who suffer from a certain death-causing syndrome  $Z$ , which simultaneously makes it uncomfortable for them to take the drug. Referring to Fig. 1, let  $Z = z_1$  and  $Z = z_0$  represent, respectively, the presence and absence of the syndrome,  $Y = y_1$  and  $Y = y_0$  represent death and survival, respectively and  $X = x_1$  and  $X = x_0$ , represent taking and not taking the drug. Assume that patients carrying the syndrome,  $Z = z_1$ , are terminal cases, for whom death occurs with probability 1, regardless of whether they take the drug. Patients not carrying the syndrome, on the other hand, incur death with probability  $p_2$  if they take the drug and with probability  $p_1$  if the don't. We will further assume

---

<sup>4</sup>Another counterfactual quantity that has been tamed by analysis is the Effect of Treatment on the Treated (ETT):  $ETT = P(Y_{x'} = y|X = x)$ . Shpitser and Pearl (2009) have shown that despite its blatant counterfactual character (e.g., “I just took an aspirin, perhaps I shouldn't have?”), ETT can be evaluated from experimental studies in many, though not all cases. It can also be evaluated from observational studies whenever a sufficient set of covariates can be measured that satisfies the back-door criterion and, more generally, in a wide class of graphs that permit the identification of conditional interventions. Numerical example of these extreme cases, and the philosophical question they evoke, are discussed in (Pearl, 2013).




Figure 1: Model generating the experimental and observational data of Eqs. (16) and (17).  $Z$  represents an unobserved confounder affecting both treatment ( $X$ ) and outcome ( $Y$ ).

$p_2 > p_1$  so that the drug appears to be a risk factor for ordinary patients, and that patients having the syndrome are more likely to avoid the drug; that is,  $q_2 < q_1$  where  $q_1 = P(x_1|z_0)$  and  $q_2 = p(x_1|z_1)$ .

Based on this model, we can compute the causal effect of the drug on death using:

$$P(y|do(x)) = \sum_z P(y|x, z)P(z) \text{ for all } y \text{ and } x \quad (14)$$

and the joint distribution  $P(x, y)$  using:

$$P(y, x) = \sum_z P(y|x, z)P(x|z)P(z) \text{ for all } y, x \quad (15)$$

Substituting the model's parameters and assuming  $r = 1/2$  gives:

$$P(y_1|do(x)) = \begin{cases} (1 + p_2)/2 & \text{for } x = x_1 \\ (1 + p_1)/2 & \text{for } x = x_0 \end{cases} \quad (16)$$

$$P(y, x) = \begin{cases} (q_2 + p_2q_1)/2 & \text{for } x = x_1 \quad y = y_1 \\ [1 - q_2 + p_1(1 - q_1)]/2 & \text{for } x = x_0 \quad y = y_1 \\ [q_2 + (1 - p_2)q_1]/2 & \text{for } x = x_1 \quad y = y_0 \\ (1 - p_1)(1 - q_1)/2 & \text{for } x = x_0 \quad y = y_0 \end{cases} \quad (17)$$

Accordingly, the bounds of Eq. (5) become:

$$(p_2 - p_1)/(p_2 + q_2/q_1) \leq PN \leq (1 - p_1)/(p_2 + q_2/q_1) \quad (18)$$

Equating the upper and lower bounds in (18) reveals that PN is identified if and only if  $q_1(1 - p_2) = 0$ , namely, if patients carrying the syndrome either do not take the drug or do not survive if they do. For intermediate value of  $p_2$  and  $q_1$ , PN is constrained to an interval that depends on all four parameters.

Figure 2 displays the lower bound (red curve) as a function of the parameter  $\beta = q_2/q_1p_2$ , for  $p_1 = 0$  and the upper bounds (green curves) for  $p_2 = 1.00, 0.5, 0.33, 0.25$ . We see that lower bound approaches 1 when  $q_2$  approaches zero, while the upper bounds are situated a factor  $1/p_2$  above the lower bound.,




Figure 2: Showing the lower bound of PN for  $p_1 = 1$  (red curve) and several upper bounds (blue curves).

## 6 Is “Guilty with Probability One” ever possible?

People tend to disbelieve this possibility for two puzzling aspects of the problem:

1. that a hypothetical, generally untestable quantity can be ascertained with probability one under certain conditions;
2. that a property of an untested individual can be assigned a probability one, on the basis of data taken from sampled population.

The first puzzle is not really surprising for students of science who take seriously the benefits of logic and mathematics. Once we give a quantity formal semantics we essentially define its relation to the data, and it not inconceivable that data obtained under certain conditions would sufficiently constrain that quantity, to a point where it can be determined exactly.

The second puzzle is the one that gives most people a shock of disbelief. For a statistician, in particular, it is a rare case to be able to say anything certain about a specific individual who was not tested directly. This emanates

from two factors. First, statisticians normally deal with finite samples, the variability of which rules out certainty in any claim, not merely about an individual but also about any property of the underlying distribution. This factor, however, should not enter into our discussion, for we have been assuming infinite samples throughout. (Readers should imagine that the numbers in Table 1 stand for millions.)

The second factor emanates from the fact that, even when we know a distribution precisely, we cannot assign a definite probabilistic estimate to a property of a specific individual drawn from that distribution. The reason is, so the argument goes, that we never know, let alone measure, all the anatomical and psychological variables that determine an individual's behavior, and, even if we knew, we would not be able to represent them in the crude categories provided by the distribution at hand. Thus, because of this inherent crudeness, the sentence "Mr. A would be dead" can never be assigned a probability one (or, in fact, any definite probability).

This argument, advanced by Freedman and Stark (1999) is incompatible with the way probability statements are used in ordinary discourse, for it implies that every probability statement about an individual would be reduced to zero or one when all relevant details are accounted for. It is inconceivable that this interpretation underlies the intent of judicial standards. By using the wording "more probable than not," lawmakers have instructed us to ignore specific features for which data is not available, and to base our determination on the most specific features for which reliable data is available. In our example, two properties of Mr. A were noted: (1) that he died and (2) that he chose to use the drug; these were properly taken into account in bounding PN as in Eq. (5). If additional properties of Mr. A become known, and deemed relevant (e.g., that he had red hair, or was left-handed), these too could, in principle, be accounted for by restricting the analysis to data representing the appropriate subpopulations. However, in the absence of such data, and knowing in advance that we will never be able to match *all* the idiosyncratic properties of Mr. A, the lawmakers' specification must be interpreted relative to the properties at hand.

## Conclusions

I agree with DFF that the issues surrounding reasoning from EoC to CoE involve the challenge of reasoning from group data to individual cases. However, the logical gulf between the two is no longer a hindrance to systematic analysis. It has been bridged by the structural semantics of counterfactuals (Balke and Pearl, 1994a,b) and now yields a coherent framework of fusing experimental

and observational data to decide individual cases of all kinds, EoC included.

I invite Dawid, Fienberg, and Faigman to reap the benefits and opportunities unleashed by the counterfactual theory of CoE.

## Acknowledgment

I am grateful to the editor for helpful comments on the first version of the manuscript. Portions of this note are based on Pearl (2011, 2012). This research was supported in parts by grants from NSF #IIS1249822 and #IIS1302448, and ONR #N00014-13-1-0153 and #N00014-10-1-0933.

## References

- BALKE, A. and PEARL, J. (1994a). Counterfactual probabilities: Computational methods, bounds, and applications. In *Uncertainty in Artificial Intelligence 10* (R. L. de Mantaras and D. Poole, eds.). Morgan Kaufmann, San Mateo, CA, 46–54.
- BALKE, A. and PEARL, J. (1994b). Probabilistic evaluation of counterfactual queries. In *Proceedings of the Twelfth National Conference on Artificial Intelligence*, vol. I. MIT Press, Menlo Park, CA, 230–237.
- CAI, Z. and KUROKI, M. (2006). Variance estimators for three ‘probabilities of causation’. *Risk Analysis* **25** 1611–1620.
- COLE, P. (1997). Causality in epidemiology, health policy, and law. *Journal of Marketing Research* **27** 10279–10285.
- DAWID, A. (2000). Causal inference without counterfactuals (with comments and rejoinder). *Journal of the American Statistical Association* **95** 407–448.
- DAWID, A., FIENBERG, S. and FAIGMAN, D. (2013). Fitting science into legal contexts: Assessing effects of causes or causes of effects? (with discussion). *Sociological Methods and Research* **32** DOI: 10.1177/0049124113515188.
- DUNCAN, O. (1975). *Introduction to Structural Equation Models*. Academic Press, New York.
- FREEDMAN, D. A. and STARK, P. B. (1999). The swine flu vaccine and Guillain-Barré syndrome: A case study in relative risk and specific causation. *Evaluation Review* **23** 619–647.

- GALLES, D. and PEARL, J. (1998). An axiomatic characterization of causal counterfactuals. *Foundation of Science* **3** 151–182.
- GREENLAND, S. (1999). Relation of probability of causation, relative risk, and doubling dose: A methodologic error that has become a social problem. *American Journal of Public Health* **89** 1166–1169.
- HAAVELMO, T. (1943). The statistical implications of a system of simultaneous equations. *Econometrica* **11** 1–12. Reprinted in D.F. Hendry and M.S. Morgan (Eds.), *The Foundations of Econometric Analysis*, Cambridge University Press, 477–490, 1995.
- HALPERN, J. (1998). Axiomatizing causal reasoning. In *Uncertainty in Artificial Intelligence* (G. Cooper and S. Moral, eds.). Morgan Kaufmann, San Francisco, CA, 202–210. Also, *Journal of Artificial Intelligence Research* 12:3, 17–37, 2000.
- PEARL, J. (1993). Comment: Graphical models, causality, and intervention. *Statistical Science* **8** 266–269.
- PEARL, J. (2000a). *Causality: Models, Reasoning, and Inference*. Cambridge University Press, New York. 2nd edition, 2009.
- PEARL, J. (2000b). Comment on A.P. Dawid’s, Causal inference without counterfactuals. *Journal of the American Statistical Association* **95** 428–431.
- PEARL, J. (2009). *Causality: Models, Reasoning, and Inference*. 2nd ed. Cambridge University Press, New York.
- PEARL, J. (2011). The algorithmization of counterfactuals. *Annals for Mathematics and Artificial Intelligence* **61** 29–39.
- PEARL, J. (2012). The causal foundations of structural equation modeling. In *Handbook of Structural Equation Modeling* (R. Hoyle, ed.). Guilford Press, New York, 68–91.
- PEARL, J. (2013). The curse of free-will and paradox of inevitable regret. *Journal of Causal Inference* **1** 255–257.
- ROBERTSON, D. (1997). The common sense of cause in fact. *Texas Law Review* **75** 1765–1800.
- ROBINS, J. and GREENLAND, S. (1989). The probability of causation under a stochastic model for individual risk. *Biometrics* **45** 1125–1138.

- SHPITSER, I. and PEARL, J. (2009). Effects of treatment on the treated: Identification and generalization. In *Proceedings of the Twenty-Fifth Conference on Uncertainty in Artificial Intelligence* (J. Bilmes and A. Ng, eds.). AUAI Press, Corvallis, OR, 514–521.
- TIAN, J. and PEARL, J. (2000). Probabilities of causation: Bounds and identification. *Annals of Mathematics and Artificial Intelligence* **28** 287–313.
- WRIGHT, S. (1921). Correlation and causation. *Journal of Agricultural Research* **20** 557–585.
- YAMAMOTO, T. (2012). Understanding the past: Statistical analysis of causal attribution. *American Journal of Political Science* **32** 237–256, DOI: 10.1111/j.1540-5907.2011.00539.x.